laropiprant


SMILES OC(=O)C[C@H]1CCc2c1n(Cc1ccc(cc1)Cl)c1c2cc(cc1S(=O)(=O)C)F
InChIKey NXFFJDQHYLNEJK-CYBMUJFWSA-N

Chemical properties

Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 5
Molecular weight (Da) 435.1

Drug properties

Molecular type Small molecule
Physiological/Surrogate Surrogate
Approved drug Yes

Database connections

Bioactivities

Receptor Activity Source
GTP Uniprot Species Family Class Type Min Avg Max Database
TP TA2R Human Prostanoid A pKi 6.1 6.1 6.1 Guide to Pharmacology
IP PI2R Human Prostanoid A pKi 5.18 5.18 5.18 ChEMBL
EP3 PE2R3 Human Prostanoid A pKi 6.05 6.05 6.05 ChEMBL
TP TA2R Human Prostanoid A pKd 7.96 7.96 7.96 ChEMBL
TP TA2R Human Prostanoid A pKi 8.53 8.53 8.53 ChEMBL
DP1 PD2R Human Prostanoid A pKd 7.98 7.98 7.98 Drug Central
DP2 PD2R2 Human Prostanoid A pKi 8.21 8.21 8.21 Drug Central
EP1 PE2R1 Human Prostanoid A pKi 8.23 8.23 8.23 Drug Central
EP2 PE2R2 Human Prostanoid A pKi 8.16 8.16 8.16 Drug Central
EP3 PE2R3 Human Prostanoid A pKi 8.22 8.22 8.22 Drug Central
FP PF2R Human Prostanoid A pKi 8.3 8.3 8.3 Drug Central
IP PI2R Human Prostanoid A pKi 8.29 8.29 8.29 Drug Central
TP TA2R Human Prostanoid A pKi 8.07 8.07 8.07 Drug Central
DP1 PD2R Human Prostanoid A pKd 10.52 10.52 10.52 ChEMBL
DP1 PD2R Human Prostanoid A pKi 9.24 9.24 9.24 ChEMBL
DP2 PD2R2 Human Prostanoid A pKi 6.13 6.13 6.13 ChEMBL
EP1 PE2R1 Human Prostanoid A pKi 5.94 5.94 5.94 ChEMBL
EP2 PE2R2 Human Prostanoid A pKi 6.87 6.87 6.87 ChEMBL
FP PF2R Human Prostanoid A pKi 5.0 5.0 5.0 ChEMBL
Receptor Activity Source
GTP Uniprot Species Family Class Type Min Avg Max Database
TP TA2R Human Prostanoid A pIC50 6.11 6.11 6.11 ChEMBL
DP1 PD2R Human Prostanoid A pIC50 8.4 9.1 10.05 ChEMBL